HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. - Wikidata - wikimedia - TriplyDB

HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis.

HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis.

http://www.wikidata.org/entity/Q33982161

about

First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy Antiretroviral drugs-based HIV prevention methods: what impact on the HIV epidemic?HIV Drug Resistance: Problems and Perspectives Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges Extreme Multidrug Resistant HIV-1 Protease with 20 Mutations Is Resistant to Novel Protease Inhibitors with P1′-Pyrrolidinone or P2-Tris-tetrahydrofuran Immune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection.HIV treatment as prevention: contradictory perspectives from dynamic mathematical models Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP)The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study Analytic review of modeling studies of ARV Based PrEP interventions reveals strong influence of drug-resistance assumptions on the population-level effectiveness How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses Evolutionary dynamics of HIV at multiple spatial and temporal scales.Suboptimal awareness and comprehension of published preexposure prophylaxis efficacy results among physicians in Massachusetts Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa Preparing for PrEP: perceptions and readiness of canadian physicians for the implementation of HIV pre-exposure prophylaxis.Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study.How can we get close to zero? The potential contribution of biomedical prevention and the investment framework towards an effective response to HIV.Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns.Effectiveness and safety of oral HIV preexposure prophylaxis for all populations Optimizing content for pre-exposure prophylaxis (PrEP) counseling for men who have sex with men: Perspectives of PrEP users and high-risk PrEP naïve men.Pre-exposure prophylaxis and the promise of combination prevention approaches What do mathematical models tell us about the emergence and spread of drug-resistant HIV?Using geospatial modelling to optimize the rollout of antiretroviral-based pre-exposure HIV interventions in Sub-Saharan Africa The distribution of sex acts and condom use within partnerships in a rural sub-Saharan African population.Modeling the impact on HIV incidence of combination prevention strategies among men who have sex with men in Beijing, China.Comparing the cost effectiveness of harm reduction strategies: a case study of the Ukraine.Targeting pre-exposure prophylaxis among men who have sex with men in the United States and Peru: partnership types, contact rates, and sexual role.How could preventive therapy affect the prevalence of drug resistance? Causes and consequences.Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance Preexposure prophylaxis for HIV prevention.The use of preexposure treatments for HIV prophylaxis HIV prevention by oral preexposure prophylaxis.Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20 Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention.Mathematical insights in evaluating state dependent effectiveness of HIV prevention interventions.Willingness to use pre-exposure prophylaxis for HIV prevention among female sex workers: a cross-sectional study in China.Pharmacists as providers of HIV pre-exposure prophylaxis.

P2860

Q21135264-B0E9C406-DF98-4389-9959-592DC582E269 Q26825761-2F68136B-7D08-49BA-899F-946E68D82559 Q26864534-DE2231E8-9612-4231-A277-2B26D2933481 Q27023352-074F906D-580B-4A34-A1CF-81C5C5AA9BFF Q27677405-164C189A-B5A6-4C3C-9A19-0697612DE101 Q27692578-4F62C0D8-0BDF-49CE-BBC3-9982E14E6458 Q28080917-1AFD3BDF-FFAE-4C81-999B-0BE59497F00B Q28477780-4A59FFCB-FE7F-4BF4-9843-16A66D0C0081 Q28484308-B895AB84-AA4D-4162-8545-528970604ABE Q28535414-AB879AB6-68A0-4683-B4A7-40D47B3D89C2 Q28552455-564B2B08-7EAA-422C-99F2-CE960391FE1E Q28742018-A9468D73-9879-4FD7-A24D-B8E2A307846B Q30416280-8735231A-14CE-44D8-A93B-A94F53395D21 Q33739550-B4546129-3354-43C3-978E-4D037A0D5388 Q33747742-B6DE0822-D4D5-439E-93A7-378640086B66 Q34061718-655BCE7B-ADE1-4B84-B444-BC9E772B7EB2 Q34081339-6090B3E8-B171-465C-8A5F-B9F2CBD31D4C Q34457045-5AC7F01B-7B75-43F9-BD49-F863A4F2F6A7 Q34481359-04DD3B0F-3F38-4FF4-86A4-4A358D9756ED Q34573789-B79E7506-8995-4B03-96E5-A598FA2E69A5 Q34677217-D8B80E05-C401-40FC-BF00-C6DEC5B6F995 Q34696493-F26B1C04-F850-45D8-87F3-79386D00F346 Q34724603-4C5D1D15-CA62-4749-94E9-ED231C748811 Q34989198-D3D7F03B-DB01-469F-954E-1325B6FA7C5E Q35067756-104A8D9E-FFD4-4458-BAAA-7A339B790C4E Q35099556-EEB584E9-6F87-49A5-90F8-9C7FA16954D2 Q35120110-8416DAC8-5E93-4F9D-A355-E88FDE184C2C Q35413055-7A09B3E2-7159-4D2A-BFAA-25C68450D019 Q35575958-32003E92-91D9-43B4-BCF8-058EA68FC570 Q35583501-7F241E41-8CCF-425B-A179-B4ADFAA97529 Q35619584-B4278D83-8AEF-42C7-A5E8-D7C35D09699F Q35717688-B36AA4EC-83B7-4775-8581-2CC5B742DAAE Q35760180-D20E3E8D-4A98-4ECF-B9F6-94F5AED8FFDA Q35765743-76FECCB1-E292-4469-8193-2032EC63C041 Q35909838-83515F8D-2ED3-4044-9A52-E567738F3A4D Q35941408-A557242C-E71C-43FF-B589-CBD5147E28DD Q36204616-1B329F32-4320-4926-BDEA-299841F47056 Q36274199-5F9EB741-09E5-435C-BBCC-C97CF0A7C894 Q36294982-EC65C65F-8F1B-47A8-8C5A-FD3F08736492 Q36409750-3392CC4A-BD4C-482D-95ED-7BB957B6065A

P2860

HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis.

http://www.wikidata.org/entity/Q33982161

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis.

@ast

HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis.

@en

type

label

HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis.

@ast

HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis.

@en

prefLabel

HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis.

@ast

HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis.

@en

P1433

Q33982161-4874CBB4-2FC1-4F4A-9DD1-85E62930238B

P1476

Q33982161-FED0B4B0-70C5-4C7C-B691-67BC6E6BDCC6

P2093

Q33982161-0FB1139F-2D28-4013-839C-34AB83A23251

Q33982161-CD1AF155-9379-4EF7-9508-C770B6494FAF

P2860

Q33982161-06257DF9-F723-4B8F-BD8B-D0018451DDF5

Q33982161-09E40A15-F6DD-4DE0-A452-862C9EECF904

Q33982161-0A8934E3-73E5-4289-8695-68E64E0F9973

Q33982161-13642E3C-4514-4AD2-B339-861E6504BAC1

Q33982161-1862B73E-49ED-433F-941F-C4209FC2C10E

Q33982161-19F8B947-EB9E-4E0B-B58E-D60B50C4D9B4

Q33982161-1EEAAAB3-DFD8-46D9-99BD-7E8B890D7017

Q33982161-2E5032F6-6E8C-47F7-B15D-ADE7A5C380F9

Q33982161-2FB3D701-0DC1-4582-80AD-A6E0526E4C99

Q33982161-3154A477-A429-4D33-8F10-65D5A284E7EF

P304

Q33982161-88EAAE2E-CE3D-46B5-A460-1FE145903688

P31

Q33982161-71E36BAD-BE55-481F-9706-F720DA0B09D9

P356

Q33982161-F4CD4573-332A-490E-8760-F1E731353F36

P407

Q33982161-60BB910A-93FC-436C-A30B-A1E9D84EEE82

P433

Q33982161-338DFA62-B85E-48F1-95AB-38ABE38056AE

P478

Q33982161-2C9978F6-4BBB-454C-BD77-BBBBC4AFEBE9

P50

Q33982161-9A8F9360-B9E8-4198-B9B8-8BDB92CAE01B

Q33982161-A4C8B073-5393-40DE-BA7B-3496816DFA59

P577

Q33982161-60C38D1D-1208-41DB-83E3-70C55CB50EB1

P5875

Q33982161-BA0444A9-0783-4BA6-99BF-3D8801795413

P698

Q33982161-DF896AF9-C2AF-4E24-9E15-F1EC61EAB2CC

P921

Q33982161-7D5D9CF2-993E-4EF8-AEE1-E3EE40742CD9

P932

Q33982161-B638C90B-439A-495C-B3F6-DA4DF96F7363

P356

PNAS.1006061107

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis.

@en

P2093

J Gerardo García-Lerma

http://www.w3.org/2001/XMLSchema#string

Virginie Supervie

http://www.w3.org/2001/XMLSchema#string

P2860

Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial

Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group

Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.

A tale of two futures: HIV and antiretroviral therapy in San Francisco.

Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection.

Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection

Could disease-modifying HIV vaccines cause population-level perversity?

Stability of transmitted drug-resistant HIV-1 species.

How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission?

P304

12381-12386

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1006061107

http://www.w3.org/2001/XMLSchema#string

P407

P433

27

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45113634

http://www.w3.org/2001/XMLSchema#string

P698

20616092

http://www.w3.org/2001/XMLSchema#string

P921

HIV transmission

P932

2901470

http://www.w3.org/2001/XMLSchema#string